VM Pharma
Sources: the KBO register on 20-11-2026; the National Bank, 2025 annual accounts filed on 04-08-2026; the Belgian Official Gazette, latest deed of 25-02-2020.
Grounds
the facts the verdict rests on, each with its source- In 2025, VM Pharma made a loss of €17,906.Annual accounts 2025 page 2
- Equity stands at €242,551, or 45.9% of the balance sheet total of €528,725. The solvency of 45.9% is higher than at 61% of the 25,414 companies filing micro accounts in retail trade (NACE 47) in 2025.Annual accounts 2025 page 2
- The 2025 accounts reached the National Bank on 04-08-2026, 4 days after the term.National Bank, filing of 04-08-2026 page 4
Representation
The signing rule is in the deed of 25-02-2020.
Articles of association, Belgian Official Gazette of 25-02-2020, deed 20311301
Ownership
The accounts in the micro format list no shareholders. holds all 100 shares.
Deed of 25-02-2020
Financial situation
Annual accounts 2021 to 2025, as filed with the National Bank
Gross margin and net resultin euro
Equity and debtsin euro
Cashin euro
| Financial year | 2021 | 2022 | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|---|---|
| Results | ||||||
| Gross margin | €105,978 | €213,180 | €131,523 | €174,740 | €131,435 | |
| Operating result | €50,234 | €127,142 | €41,682 | €86,990 | €31,565 | |
| Net result | €34,607 | €92,490 | €28,895 | €14,987 | -€17,906 | |
| Balance sheet at the closing date | ||||||
| Equity | €124,125 | €216,574 | €245,470 | €260,457 | €242,551 | |
| Debts | €190,736 | €237,520 | €169,261 | €131,987 | €286,174 | |
| Debts due after more than one year | €116,460 | €98,299 | €79,932 | €61,355 | €42,565 | |
| Debts due within one year | €74,276 | €139,221 | €89,329 | €70,632 | €243,609 | |
| Cash | €42,255 | €126,714 | €24,828 | €9,415 | €54,967 | |
| Balance sheet total | €314,860 | €454,095 | €414,731 | €392,444 | €528,725 | |
| Ratios | ||||||
| Solvency | 39.4% | 47.7% | 59.2% | 66.4% | 45.9% | |
| Liquidity | 2.22 | 2.27 | 3.15 | 3.87 | 1.77 | |
Source: Annual accounts 2025, micro format, filed on 04-08-2026 (2026-00383885); Annual accounts 2024, micro format, filed on 24-06-2025 (2025-00189923); Annual accounts 2021 to 2023, filed from 22-06-2022 to 17-06-2024 (2022-20080380, 2023-00172876, 2024-00155512).
The operating result of 2025 is €31,565, the net result a loss of €17,906.
Debts rose by €154,187 in 2025, of which €139,802 to suppliers.
The 2025 annual accounts state no amount of overdue tax or social security (RSZ) debts.
VM Pharma states no turnover; the micro format does not require it. The gross margin, what is left after purchases, fell from €174,740 to €131,435.
Board, signature and ownership
Position on 20-11-2026 according to the deeds in the Belgian Official Gazette and the annual accounts
Who represents the company
The signing rule is in the deed of 25-02-2020.
Articles of association, Belgian Official Gazette of 25-02-2020, deed 20311301
Board
one director in officeOwnership and group
Shareholders
The accounts in the micro format list no shareholders. holds all 100 shares.
Deed of 25-02-2020
Events and comparison
Every event since the founding, newest first
Annual accounts 2025 filed, 4 days late.
NBB filingWeakest financial year. The net result drops to -€17,906, the lowest from 2020 to 2025.
FinancialAnnual accounts 2024 filed, 37 days before the deadline.
NBB filingAnnual accounts 2023 filed, 44 days before the deadline.
NBB filingAnnual accounts 2022 filed, 32 days before the deadline.
NBB filingHighest result from 2020 to 2025. The operating result of €127,142 and the net result of €92,490 are both a record.
FinancialEquity above €200,000. With a profit in every financial year since 2020, equity grows to €216,574.
FinancialAnnual accounts 2021 filed, 39 days before the deadline.
NBB filingEquity above €100,000. With a profit in every financial year since 2020, equity grows to €124,125.
FinancialAnnual accounts 2020 filed, 27 days late.
NBB filingIncorporation. Founding capital of €50,000, 100 shares. Founded by . appointed as director. Published on 25-02-2020.
Gazette, deed 20311301First establishment. Théophile Vander Elststraat 42, Watermael-Boitsfort.
Comparable companies, two years later
In July 2024, 930 companies had the same profile as VM Pharma has now: small, 5 to 10 years old, solvency 30% or more and a small loss. Two years later 92.7% were still trading, 5.6% had stopped another way and 1.7% had gone bankrupt.
The return on assets of VM Pharma, -3.4%, is higher than at 26% of the 24,603 companies filing micro accounts in retail trade (NACE 47) in 2025.
Other findings
Peppol
Reachable for e-invoices since 23-09-2025, under 0208:0743948725.
Sanctions lists
Sources and method
Where each fact in this report comes from
| Source | What | Date | Reference |
|---|---|---|---|
| KBO register | Registration, legal situation, activity, establishment units | 20-11-2026 | KBO 0743.948.725 |
| National Bank of Belgium | Annual accounts 2025, micro format | 04-08-2026 | 2026-00383885 |
| National Bank of Belgium | Annual accounts 2024, micro format | 24-06-2025 | 2025-00189923 |
| National Bank of Belgium | Annual accounts 2021 to 2023 | 22-06-2022 to 17-06-2024 | 2022-20080380, 2023-00172876, 2024-00155512 |
| Belgian Official Gazette | Articles of association with the signing rule | 25-02-2020 | deed 20311301 |
| Peppol Directory | Registration for e-invoices | 23-09-2025 | 0208:0743948725 |
| Sanctions lists EU, UN, US (OFAC) and UK | Comparison of the name | 19-11-2026 | |
| Checked | Checked score, bankruptcy probability, credit, comparable companies | 19-11-2026 | bankruptcy model of 2 October 2026 |
Method
Checked score. A number from 0 to 100. The bankruptcy probability sets the class, from Critical to Excellent; within the class, the comparison with sector peers on solvency, liquidity, profitability and growth counts for half.
Bankruptcy probability. The probability that the company goes bankrupt within 12 months, estimated from the KBO register, the annual accounts and the Gazette with the bankruptcy model of 2 October 2026, computed on 19-11-2026.
Credit. The credit is a tenth of equity, weighted by the score, and never more than a tenth of turnover. With negative equity there is no credit.
Comparable companies. Companies of the same size, age, solvency and profitability at an earlier date, followed two years later in the KBO register and the Gazette.
The scores and ratios are Checked's own calculations, not a credit decision.